Valuation: Takeda Pharmaceutical Company Limited

Market Cap 9,011B 57.13B 50.76B 47.38B 43.18B 81.44B 5,492B 82.2B 573B 222B 2,808B 214B 210B P/E 2027 *
44.7x
P/E 2028 * 28.4x
Enterprise Value 12,917B 81.9B 72.77B 67.92B 61.9B 117B 7,873B 118B 822B 318B 4,025B 307B 301B EV / Sales 2027 *
2.75x
EV / Sales 2028 * 2.65x
Free-Float
99.25%
Yield 2027 *
3.62%
Yield 2028 * 3.69%
1 week-5.31%
Current month-3.61%
1 month-1.01%
3 months+8.48%
6 months-3.16%
Current year+18.66%
1 week 31.22
Extreme 31.22
33.2
1 month 31.22
Extreme 31.22
33.49
3 years 22.95
Extreme 22.95
33.49
5 years 22.95
Extreme 22.95
33.49
10 years 22.95
Extreme 22.95
49.6
Manager TitleAgeSince
Chief Executive Officer 56 2024-12-31
Director of Finance/CFO 48 2024-03-31
Chief Tech/Sci/R&D Officer 48 2022-01-31
Director TitleAgeSince
Director/Board Member 61 2015-05-31
Director/Board Member 73 2018-12-31
Director/Board Member 48 2024-05-31
Change 5-day change 1-year change 3-year change Capi.($)
-2.25%-2.20%+26.23%+7.50% 57.13B
-0.61%-3.43%+36.07%+117.61% 1,019B
-1.02%-5.60%+35.72%+64.82% 617B
+1.11%-0.58%+12.36%+78.27% 464B
+0.34%-3.01%+61.79%+41.79% 356B
-0.95%-4.05%+20.54%+40.33% 333B
-1.46%-2.89%+10.57%+26.54% 267B
-1.35%-5.43%-6.17%+8.82% 244B
-1.04%-2.79%+35.30%+54.42% 218B
-1.87%-4.10%+28.44%+97.54% 179B
Average -0.76%-3.39%+26.09%+53.76% 410.8B
Weighted average by Cap. -0.60%-3.33%+29.03%+70.18%

Financials

2027 *2028 *
Net sales 4,704B 29.82B 26.5B 24.73B 22.54B 42.51B 2,867B 42.91B 299B 116B 1,466B 112B 110B 4,794B 30.4B 27.01B 25.21B 22.98B 43.33B 2,922B 43.73B 305B 118B 1,494B 114B 112B
Net income 196B 1.25B 1.11B 1.03B 942M 1.78B 120B 1.79B 12.5B 4.84B 61.23B 4.68B 4.58B 323B 2.05B 1.82B 1.7B 1.55B 2.92B 197B 2.94B 20.53B 7.96B 101B 7.68B 7.52B
Net Debt 3,907B 24.77B 22.01B 20.54B 18.72B 35.31B 2,381B 35.64B 249B 96.32B 1,217B 92.99B 90.97B 3,702B 23.47B 20.86B 19.47B 17.74B 33.46B 2,257B 33.77B 236B 91.28B 1,154B 88.13B 86.22B
Logo Takeda Pharmaceutical Company Limited
Takeda Pharmaceutical Co Ltd is a Japan-based company mainly engaged in the research, development, manufacturing and global sales of a wide range of pharmaceuticals. Its main business areas are divided into six, including gastroenterology, rare diseases, plasma-derived therapies, oncology (cancer), vaccines, and neuroscience (neuropsychiatric disorders). In research and development, the Company focuses on three priority disease areas, including gastroenterology and inflammatory diseases, neuroscience, and oncology, and also focuses on plasma-derived therapies.
Employees
-
Date Price Change
26-10-02 €31.23 -2.25%
26-10-01 €31.95 -1.39%
26-09-30 €32.40 +0.22%
26-09-29 €32.33 -2.62%
26-09-28 €33.20 +0.67%
Trader
Investor
Global
Quality
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
16
Last Close Price
5,643.00JPY
Average target price
6,622.06JPY
Spread / Average Target
+17.35%

Quarterly revenue - Rate of surprise